Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

-Ahead of print
-Authors' Accepted
    Manuscripts
new!
-Current Issue
-Archive
-Acknowledgments
-Special Issues
-Browse by Category

Manuscript Submission

-Online Submission
-Online Review
-Instruction for Authors
-Instruction for Reviewers
-English Corner new!

About AJA

-About AJA
-Editorial Board
-Contact Us
-News

Resources & Services

-Advertisement
-Subscription
-Email alert
-Proceedings
-Reprints

Download area

-Copyright licence
-EndNote style file
-Manuscript word template
-Guidance for AJA figures
    preparation (in English)

-Guidance for AJA figures
    preparation (in Chinese)

-Proof-reading for the
    authors

-AJA Club (in English)
-AJA Club (in Chinese)

 
Abstract

Volume 11, Issue 5 (September 2009) 11, 629–637; 10.1038/aja.2009.48

Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study

Ferdinando Fusco1, Riccardo Sicuteri2, Andrea Rossi2, Stathis Kontodimas3, Jose Maria Haro4, Ciro Imbimbo1 and Vincenzo Mirone for the Italian EDOS Study Group*

1 Clinica Urologica – Università Federico II, Napoli 80100, Italy
2 Ely Lilly Italia, Firenze 50019, Italy
3 Eli Lilly and Company, Windlesham, Surrey GU20 6PH, UK
4 Fundació Sant Joan de Déu, Esplugues de Llobregat 08950, Spain

* Member of the Italian EDOS study group are listed in Appendix

Correspondence: Dr Ferdinando Fusco, ferdinando-fusco@libero.it

Received: 5 July 2009 Accepted: 10 July 2009 Published online: 24 August 2009

Abstract

The Erectile Dysfunction Observational Study (EDOS) is a 6-months observational prospective multicentric study enrolling men with erectile dysfunction (ED) who asked, to be started on a treatment or to change a previous treatment. Aims of the study were to analyse the pattern of treatment and compare the efficacy of treatments used. Patients were enrolled during a normal hospital visit and were prescribed a treatment for ED. They were asked at baseline and after 3 and 6 months, to answer a set of questions from the International Index of Erectile Function, Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) and Short Form of the Psychological and Interpersonal Relationships Scale questionnaires (SF-PAIRS). Clinicians were free to prescribe any therapy for ED available in the market, and to change therapy at any time during the study. Out of 1 338 patients, available for analysis at 6 months, 624 (47%) changed their treatment during the study and 714 (53%) continued with the drug prescribed at baseline. Patients assuming tadalafil had a significantly higher probability of maintaining the same treatment compared to sildenafil or vardenafil. There was no clinically significant difference in terms of efficacy, patient satisfaction, self-confidence and spontaneity between the different inhibitors of PDE5. The 'time concerns' domain score of SF-PAIRS, was statistically better in patients assuming tadalafil. In conclusion sildenafil, vardenafil and tadalafil show similar efficacy in the clinical practice. However, patients receiving tadalafil display a lower risk to discontinue or change the treatment.

Keywords: clinical practice, Italy, phosphodiesterase type 5 inhibitors, sildenafil, tadalafil, vardenafil

PDF | PDF | 中文摘要 |

 
Browse:  4312
 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.